EUR/USD 1.14318
-0.079%
Gold 4150.19
-0.353%
Oil 69.057
0.706%
USD/JPY 161.922
-0.097%
GBP/USD 1.33871
-0.019%
GBP/JPY 216.772
-0.114%
Browse More
  • English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
Ukrainian President Zelensky: Ukraine is the source of the coalitions "extraordinary" defense capabilities.Ukrainian President Zelensky: The defense level against Russian attack drones has been raised to 90%.Ukrainian President Zelensky: Ukraine kills nearly 40,000 Russian soldiers every month.Raymond Certified Financial: Initiated coverage research on SpaceX (SPCX.O) with a "Strong Buy" rating and a target price of $800.On July 7th, the National Healthcare Security Administration issued a risk warning. During the selection phase of the 12th batch of national centralized drug procurement (hereinafter referred to as "the 12th batch of centralized procurement"), a company producing imported original drugs submitted a so-called "expert recommendation letter jointly signed by 78 doctors from 31 hospitals," attempting to influence the procurement process. After verifying with each of the "signing experts," it was found that over 80% of the signatures were fake, involving instances of sales personnel forging signatures, misappropriating images from other sources, and fabricating identities. The few signatures that were indeed from the experts were mostly induced by sales personnel under the guise of "after-sales follow-up" or "survey questionnaires." Currently, this drug has passed expert review through normal procedures and has been officially included in the 12th batch of centralized procurement. The administration is currently organizing national pharmaceutical institutions to submit their proposed procurement quantities. The National Healthcare Security Administration firmly opposes companies interfering with the centralized drug procurement process through improper means and solemnly reminds all pharmaceutical companies not to use illegal or irregular methods to interfere with centralized procurement; otherwise, they will bear the consequences.

Price Analysis: EUR/JPY Daily Rising Wedge Targeting 143.00

Daniel Rogers

Nov 23, 2022 16:01

 截屏2022-11-23 上午9.53.21.png

 

The EUR/JPY continues to consolidate within an ascending wedge, after ending Tuesday with tiny losses of 0.04% due to a risk-on sentiment. At the start of the Asian trading session, the EUR/JPY exchange rate is 145.48, representing a slight gain of 0.01%.

 

As noted previously, a rising wedge emerged on the EUR/JPY daily chart, with the bulk of daily lows acting as dynamic support after the 50-day Exponential Moving Average (EMA). In spite of the fact that the cross continues to move steadily, there has been less price action during the past four days. This would suggest that the EUR/JPY exchange rate is stable or that a breakout is near.

 

If the EUR/JPY reaches 146.00, it could accelerate a rally toward the year-to-date (YTD) highs near 148.40; however, buyers must first overcome crucial resistance levels. The first is the rising wedge top trendline close to 146.50, followed by the 9 November daily high at 147.11. After the psychological 148.00 is reached, the next objective will be 149.00.

 

If the EUR/JPY breaks below the rising wedge, the 50-day exponential moving average (EMA) around 144.12 would provide first support. A breach of this level will expose the 143.00 level, followed by the November 11 swing low of 142.54.

Suggestion